EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
171 hedge funds and large institutions have $540M invested in Eagle Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 66 increasing their positions, 54 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
15% less capital invested
Capital invested by funds: $633M → $540M (-$92.7M)
Holders
171
Holding in Top 10
–
Calls
$1.34M
Puts
$16K
Top Buyers
| 1 | +$16.6M | |
| 2 | +$7.57M | |
| 3 | +$6.28M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.44M |
| 5 |
Morgan Stanley
New York
|
+$4.92M |
Top Sellers
| 1 | -$20.5M | |
| 2 | -$16.7M | |
| 3 | -$8.21M | |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
-$6.57M |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$3.75M |